Cargando…

Noninferiority trials

Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that superiority trials do not: no internal demonstration of assay sensitivity, no single conse...

Descripción completa

Detalles Bibliográficos
Autor principal: Snapinn, Steven M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59590/
https://www.ncbi.nlm.nih.gov/pubmed/11714400
http://dx.doi.org/10.1186/cvm-1-1-019
_version_ 1782120079861743616
author Snapinn, Steven M
author_facet Snapinn, Steven M
author_sort Snapinn, Steven M
collection PubMed
description Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that superiority trials do not: no internal demonstration of assay sensitivity, no single conservative analysis approach, lack of protection from bias by blinding, and difficulty in specifying the noninferiority margin. Noninferiority trials may sometimes be necessary when a placebo group can not be ethically included, but it should be recognized that the results of such trials are not as credible as those from a superiority trial.
format Text
id pubmed-59590
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-595902001-11-06 Noninferiority trials Snapinn, Steven M Curr Control Trials Cardiovasc Med Commentary Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that superiority trials do not: no internal demonstration of assay sensitivity, no single conservative analysis approach, lack of protection from bias by blinding, and difficulty in specifying the noninferiority margin. Noninferiority trials may sometimes be necessary when a placebo group can not be ethically included, but it should be recognized that the results of such trials are not as credible as those from a superiority trial. BioMed Central 2000 2000-07-31 /pmc/articles/PMC59590/ /pubmed/11714400 http://dx.doi.org/10.1186/cvm-1-1-019 Text en Copyright © 2000 Current Controlled Trials Ltd
spellingShingle Commentary
Snapinn, Steven M
Noninferiority trials
title Noninferiority trials
title_full Noninferiority trials
title_fullStr Noninferiority trials
title_full_unstemmed Noninferiority trials
title_short Noninferiority trials
title_sort noninferiority trials
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59590/
https://www.ncbi.nlm.nih.gov/pubmed/11714400
http://dx.doi.org/10.1186/cvm-1-1-019
work_keys_str_mv AT snapinnstevenm noninferioritytrials